Intellect Design Arena (INTELLECT) near Rs 505: Is the 16% share-price crash justified when AI revenue is growing but profits are not?
Read More Pharma Industry News Could Biogen and UCB finally crack one of biotech’s toughest lupus markets? Biogen and UCB have a lupus win, but one more Phase 3 test decides the story. See why dapirolizumab pegol matters now. byPallavi MadhirajuJune 1, 2026